Childhood cancer and other rare pediatric diseases are heartbreaking.
But should certain FCPA settlement amounts fund pediatric disease research?
Representative Jennifer Wexton (D-Va) thinks so as she, along with co-sponsors Tom Cole (R-OK), Peter Welch (D-VT) and Gus Bilirakis (R-FL), recently introduced H.R. 6556 – a bill that seeks to amend the FCPA’s anti-bribery provisions by transferring FCPA civil settlement amounts by pharmaceutical companies to pediatric disease research. The bill is titled the Gabriella Miller Kids First Research Act 2.0. Miller (pictured – died of cancer in 2013 at the age of 10).